Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04606394 · ClinicalTrials.gov registry record · Phase 4

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

A Phase 4 study of COPD, sponsored by Pulmonary Research Institute of Southeast Michigan.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT04606394 is a Phase 4 study of COPD that has completed, run by Pulmonary Research Institute of Southeast Michigan. The registered enrollment target is 30 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04606394, a Phase 4 study of COPD, has completed, sponsored by Pulmonary Research Institute of Southeast Michigan.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF maneuver and to relate this PIF measurement to meaningful clinical outcomes in COPD patients

Conditions Studied

Interventions

  • DRUG Trelegy Ellipta 100/62.5/25Mcg Inh 30D
  • DRUG Ventolin 90Mcg/Actuation Inhalation Aerosol

Study Locations (1)

Michigan

  • Pulmonary Research Institute of Southeast Michigan - Farmington Hills

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-12-02
Est. Completion 2021-12-15
Phase Phase 4

What the Registry Record Tells You About NCT04606394

The ClinicalTrials.gov registry entry for NCT04606394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The listed sponsor is Pulmonary Research Institute of Southeast Michigan, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Trelegy Ellipta 100/62.5/25Mcg Inh 30D is the first listed.

NCT04606394 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT04606394 about?

NCT04606394 is a clinical study titled "Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD". The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF maneuver and to relate t...

What is the current status of trial NCT04606394?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2020-12-02. Estimated completion is 2021-12-15.

What conditions does trial NCT04606394 study?

This clinical trial studies the following conditions: COPD.

What interventions are being tested in trial NCT04606394?

The interventions under investigation include: Trelegy Ellipta 100/62.5/25Mcg Inh 30D (DRUG), Ventolin 90Mcg/Actuation Inhalation Aerosol (DRUG).

Who is sponsoring clinical trial NCT04606394?

This trial is sponsored by Pulmonary Research Institute of Southeast Michigan, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04606394 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.